262 related articles for article (PubMed ID: 27681573)
41. Reidentification and antifungal susceptibility profile of Candida guilliermondii and Candida famata clinical isolates from a culture collection in Argentina.
Taverna CG; Córdoba S; Vivot M; Szusz W; Vivot W; Bosco-Borgeat ME; Davel G
Med Mycol; 2019 Apr; 57(3):314-323. PubMed ID: 29955881
[TBL] [Abstract][Full Text] [Related]
42. Candida nivariensis as an etiologic agent of vulvovaginal candidiasis in a tertiary care hospital of New Delhi, India.
Sharma C; Wankhede S; Muralidhar S; Prakash A; Singh PK; Kathuria S; Kumar DA; Khan N; Randhawa HS; Meis JF; Chowdhary A
Diagn Microbiol Infect Dis; 2013 May; 76(1):46-50. PubMed ID: 23537782
[TBL] [Abstract][Full Text] [Related]
43. Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient.
Krogh-Madsen M; Arendrup MC; Heslet L; Knudsen JD
Clin Infect Dis; 2006 Apr; 42(7):938-44. PubMed ID: 16511756
[TBL] [Abstract][Full Text] [Related]
44. Usefulness of a multiplex PCR for the rapid identification of Candida glabrata species complex in Mexican clinical isolates.
Reyes-Montes MDR; Acosta-Altamirano G; Duarte-Escalante E; Salazar EG; Martínez-Herrera E; Arenas R; González G; Frías-De-León MG
Rev Inst Med Trop Sao Paulo; 2019 Aug; 61():e37. PubMed ID: 31411267
[TBL] [Abstract][Full Text] [Related]
45. Candida infection in the intensive care unit: A study of antifungal susceptibility pattern of Candida species in Milad hospital, Tehran, Iran.
Alimehr S; Shekari Ebrahim Abad H; Fallah F; Rahbar M; Mohammadzadeh M; Vossoghian S; Rafeei Tabatabaee S; Roudbary M; Zaini F
J Mycol Med; 2015 Dec; 25(4):e113-7. PubMed ID: 26563641
[TBL] [Abstract][Full Text] [Related]
46. Low Level of Antifungal Resistance in Iranian Isolates of Candida glabrata Recovered from Blood Samples in a Multicenter Study from 2015 to 2018 and Potential Prognostic Values of Genotyping and Sequencing of
Arastehfar A; Daneshnia F; Zomorodian K; Najafzadeh MJ; Khodavaisy S; Zarrinfar H; Hagen F; Zare Shahrabadi Z; Lackner M; Mirhendi H; Salehi M; Roudbary M; Pan W; Kostrzewa M; Boekhout T
Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 30936110
[TBL] [Abstract][Full Text] [Related]
47. [In vitro activity of amphotericin B, fluconazole and itraconazole against Candida glabrata strains isolated from clinical samples].
Hüseyin A; Sancak B; Arikan S
Mikrobiyol Bul; 2007 Apr; 41(2):235-44. PubMed ID: 17682710
[TBL] [Abstract][Full Text] [Related]
48. [Epidemiology of candidemia: results of a one month French hospitals-based surveillance study in 2004].
Eloy O; Blanc V; Pina P; Gaudart A; Bressolle ML; Plainvert C; Decousser JW; Pangon B; Allouch PY;
Pathol Biol (Paris); 2006; 54(8-9):523-30. PubMed ID: 17029814
[TBL] [Abstract][Full Text] [Related]
49. Potential Use of MALDI-ToF Mass Spectrometry for Rapid Detection of Antifungal Resistance in the Human Pathogen Candida glabrata.
Vella A; De Carolis E; Mello E; Perlin DS; Sanglard D; Sanguinetti M; Posteraro B
Sci Rep; 2017 Aug; 7(1):9099. PubMed ID: 28831086
[TBL] [Abstract][Full Text] [Related]
50. Detection of triazole resistance among Candida species by matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS).
Saracli MA; Fothergill AW; Sutton DA; Wiederhold NP
Med Mycol; 2015 Sep; 53(7):736-42. PubMed ID: 26162474
[TBL] [Abstract][Full Text] [Related]
51. Synergistic effects of tacrolimus and azole antifungal compounds in fluconazole-susceptible and fluconazole-resistant Candida glabrata isolates.
Denardi LB; Mario DA; Loreto ÉS; Santurio JM; Alves SH
Braz J Microbiol; 2015 Mar; 46(1):125-9. PubMed ID: 26221097
[TBL] [Abstract][Full Text] [Related]
52. Echinocandin resistance and population structure of invasive Candida glabrata isolates from two university hospitals in Germany and Austria.
Klotz U; Schmidt D; Willinger B; Steinmann E; Buer J; Rath PM; Steinmann J
Mycoses; 2016 May; 59(5):312-8. PubMed ID: 26806376
[TBL] [Abstract][Full Text] [Related]
53. Old and new pathogenic Nakaseomyces species: epidemiology, biology, identification, pathogenicity and antifungal resistance.
Angoulvant A; Guitard J; Hennequin C
FEMS Yeast Res; 2016 Mar; 16(2):fov114. PubMed ID: 26691882
[TBL] [Abstract][Full Text] [Related]
54. Prevalence of Candida bracarensis and Candida nivariensis in a Spanish collection of yeasts: comparison of results from a reference centre and from a population-based surveillance study of candidemia.
Cuenca-Estrella M; Gomez-Lopez A; Isla G; Rodriguez D; Almirante B; Pahissa A; Rodriguez-Tudela JL;
Med Mycol; 2011 Jul; 49(5):525-9. PubMed ID: 21198347
[TBL] [Abstract][Full Text] [Related]
55. Multiplex PCR designed to differentiate species within the Candida glabrata complex.
Dudiuk C; Morales-López SE; Podesta V; Macedo D; Leonardelli F; Vitale RG; Tosello ME; Cabeza MS; Biasoli M; Gamarra S; Garcia-Effron G
Rev Iberoam Micol; 2017; 34(1):43-45. PubMed ID: 27810263
[TBL] [Abstract][Full Text] [Related]
56. Candidiasis by
Hernando-Ortiz A; Eraso E; Quindós G; Mateo E
J Fungi (Basel); 2021 Nov; 7(12):. PubMed ID: 34946981
[No Abstract] [Full Text] [Related]
57. Species distribution and antifungal susceptibility of Candida bloodstream isolates in a tertiary medical center in Israel.
Samra Z; Yardeni M; Peled N; Bishara J
Eur J Clin Microbiol Infect Dis; 2005 Sep; 24(9):592-5. PubMed ID: 16172856
[TBL] [Abstract][Full Text] [Related]
58. Species distribution and susceptibility profile of yeasts isolated from blood cultures: results of a multicenter active laboratory-based surveillance study in Argentina.
Córdoba S; Vivot W; Bosco-Borgeat ME; Taverna C; Szusz W; Murisengo O; Isla G; Davel G;
Rev Argent Microbiol; 2011; 43(3):176-85. PubMed ID: 22430989
[TBL] [Abstract][Full Text] [Related]
59. Molecular epidemiology, antifungal susceptibility and virulence factors of Candida glabrata complex strains in Kayseri/Turkey.
Kaan Ö; Koç AN; Atalay MA; Mutlu Sarigüzel F
Microb Pathog; 2021 May; 154():104870. PubMed ID: 33774107
[TBL] [Abstract][Full Text] [Related]
60. Comparison of EUCAST and CLSI broth microdilution methods for the susceptibility testing of 10 systemically active antifungal agents when tested against Candida spp.
Pfaller MA; Castanheira M; Messer SA; Rhomberg PR; Jones RN
Diagn Microbiol Infect Dis; 2014 Jun; 79(2):198-204. PubMed ID: 24736096
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
